• Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    • Interviews – Academia
    • Interviews – Industry
  • Issues
  • Subscribe
  • Board
  • Advertise
Facebook Twitter Instagram
Trending
  • BioAsia 2023 to be held in February 24-26 in Telangana, India
  • Praj Industries and ESIIC partner to further bioeconomy in Egypt
  • Who is The Real Anthony Fauci? A true Doctor, liar, pharma profiteer or a totalitarian?
  • Guestorial: MALNUTRITION ACCELERATES THE METABOLIC AGE
  • Event: Australia’s biggest week in biotech kicks off in Perth
  • $3 trillion growth reported for biotech sector in USA
  • Event : FABA’s Whale Tank Event – “Venture Capital – Biotech Start-up Connect”
  • Vaccination, Rising Deaths, And The False Narrative
Biotech Express Magazine
  • Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    1. Interviews – Academia
    2. Interviews – Industry
    Featured
    January 16, 20211

    Interview – Prof Rajeev K Varshney “The Youngest Indian Scientist (47)” who achieved an h-index of 100 recently

    Recent
    July 26, 2022

    We are making best hygiene solutions through Biotech applications: Dr Rachna Dave, founder MicroGO

    March 30, 2022

    Interview- Bioenergy: India’s Ministry of New and Renewable Energy started almost four decades ago…but did not catch up…, Professor Ashok Pandey

    January 24, 2022

    Interview: Prof Kailash Chander Bansal, Secretary, National Academy of Agricultural Sciences (NAAS), India

  • Issues
  • Subscribe
  • Board
  • Advertise
Biotech Express Magazine
You are at:Home»Articles»For India, From India: A strategic battle to win against both the pandemic and the public psychology

For India, From India: A strategic battle to win against both the pandemic and the public psychology

0
By Biotech Express on July 19, 2021 Articles, Articles- Editorials, SARS- CoV2 & COVID-19 Updates

Nabanita Roy Chattopadhyay and Tathagata Choudhuri*

Department of Biotechnology, Visva-Bharati, Santiniketan.
*E-mail: tathagata.choudhuri@visva-bharati.ac.in, Mobile: +919861724726.

 

COVID-19 pandemic, the biggest global issue nowadays, is universally agreed to be won by effective vaccination only, as no conclusive drug and/or treatment strategy is available till date. In comparison to the developed countries like the United Kingdom and the United States of America, the rate of vaccination in India is lower and the percentage of vaccinated persons are much lower.

Despite the Central Government’s awareness campaigns and vaccination offers via CoWIN site, this lower rate of vaccination is heightening the risk of the speculated third wave of COVID. But there are a few reasons behind the lower rate, which should be addressed as early and widely as possible. Firstly, safety data should be introduced in the awareness programmes. Most of the general public are afraid of the possible adverse effects of any vaccine. Including COVAXIN, all available vaccines against COVID-19 are developed fast and are issued an Emergency Use Authorization (EUA). This information creates a panic in public, and it results in unacceptance of vaccines even in health care workers (HCW).

Another major reason involves the activities of media and social sites. Though most of the print- and electronic media try to deliver the accurate information, insufficient scientific analysis in those news generate ill-informed public. Some of these people vomit those undigested bogus along with their own unrealistic speculations on social media platforms; thus, eventually destroying the efforts of the Government. Some examples of such ‘social media information’ for side effects of vaccination are as follows: lower sperm-count, decreased survival rate in normal people, infertility in women, increased risks for other diseases, risk of heart attacks after vaccination, etc.

The most threatening idea spreading in social media platforms is, any vaccine is useless and unnecessary at all. As the SARS-CoV-2 virus causing COVID-19 shows less ‘killing effect’ compared to some other viruses like Ebola and Lassa virus, those ill-informed public cannot understand the need of vaccination. They better like to wait for natural immunity after getting a mild infection with SARS-CoV-2. Therefore, the Government should put some extra effort to design campaigns to make people understand that the virus does not ask the victim for ‘mild’ or ‘major’ attack.

In contrast to the other countries, India has designed its own vaccine using the inactivated viral agent; most of the other available vaccines use a SARS-CoV-2 protein, or viral mRNA, along with some vector from other virus. But using the whole virus particle, though inactivated, has some specific benefits that cannot be expected form other vaccine development strategies.

Before discussing the benefits of inactivated viral vaccine, it must be noted that ‘inactivation’ of a virus effectively ceases its growth inside the host body. Therefore, the ‘inactivated virus’ vaccine if prepared cautiously is safe and cannot generate active live viruses in the acceptor. This vaccine, brand name ‘COVAXIN’, is reported to show more than 80% efficacy; this means, if one hundred people are vaccinated with COVAXIN, more than eighty people will have effective immunity in them after the second dose. This efficacy rate is undoubtedly appreciable; thus making this vaccine acceptable and approvable by the World Health Organization (WHO) which despite its effectiveness and safety faced some initial rejections.

COVAXIN, made in India by Bharat Biotech, confers a wide range of immune responses in the vaccinated person. As the whole ‘body’ of the virus is used, all the viral proteins are available for generating immune responses. As a result, a polyclonal antibody titre is expected in each vaccinated person, and more effective protection is expected. Probably, this is the reason that COVAXIN shows effectivity against the Delta-variety of the SASR-CoV-2. Due to mutations, the initial SARS-CoV-2 virus has generated more infectious variants, and the Delta-variety is considered the most infective one. Mutations can change viral proteins; therefore, the other vaccines which used one or two viral proteins for generating antibody responses in the recipient, may not generate affective immunity if the mutation(s) changes that selected viral protein inside the virus. This problem is not expected in COVAXIN. Generation of antibodies against at least one (or even more) unaltered viral protein(s) is expected, even when a few other viral proteins become mutated. This can make COVAXIN the ‘vaccine of choice’ for its broad-spectrum protection.

In conclusion, to combat the onset of the third wave of COVID, the Government of India should emphasize the campaigning strategies; so that, the afore-mentioned hesitancy for vaccination can be cured. The scientific phenomenon should also be used for generating public awareness, in a simple layman’s language, to reduce hesitancy for vaccination and increase the choice for COVAXIN. In this way, we all should stand for India, by using vaccine from India, for developing a better India set aside foreign counterparts if they are not willing to accept Indian sciences.

Published in July 2021 Issue

 

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Biotech Express
  • Website
  • Facebook
  • Twitter
  • LinkedIn

ISSN: 2454-6968 | Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports, Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology, Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurosciences, Genetics, Medical Sciences, BioPharma etc.

Related Posts

Who is The Real Anthony Fauci? A true Doctor, liar, pharma profiteer or a totalitarian?

Guestorial: MALNUTRITION ACCELERATES THE METABOLIC AGE

Event : FABA’s Whale Tank Event – “Venture Capital – Biotech Start-up Connect”

Leave A Reply Cancel Reply

Current Issue – October 2022
Upcoming Event

                   VIEW SUBSCRIPTION PLANS

JOBS/NOTIFICATIONS

   

         CLICK HERE FOR RECENT NOTICES

Recent Posts
  • BioAsia 2023 to be held in February 24-26 in Telangana, India January 10, 2023
  • Praj Industries and ESIIC partner to further bioeconomy in Egypt November 10, 2022
  • Who is The Real Anthony Fauci? A true Doctor, liar, pharma profiteer or a totalitarian? November 1, 2022
  • Guestorial: MALNUTRITION ACCELERATES THE METABOLIC AGE October 31, 2022
  • Event: Australia’s biggest week in biotech kicks off in Perth October 26, 2022
  • $3 trillion growth reported for biotech sector in USA October 25, 2022
  • Event : FABA’s Whale Tank Event – “Venture Capital – Biotech Start-up Connect” September 21, 2022
  • Vaccination, Rising Deaths, And The False Narrative September 20, 2022
  • Guestorial: Genome Mapping Techniques and its Application in Aquaculture September 19, 2022
  • Bombay HC Issues Notice To Bill Gates, Serum Institute, DGCI, Others Over Plea On Alleged ‘Vaccine Death’ September 5, 2022
  • Deaths due Covid-19 vaccines should be compensated by vaccine makers: Expert hope on Kerala HC remark August 21, 2022
  • Maker of Dolo-650, pandemic’s ‘magic pill’, faces income tax searches and PIL petitions August 20, 2022
  • Anthony Fauci, Controversial US Top-doc FINALLY, To Retire By Year-end August 20, 2022
  • SII’s Cervevac: The new DCGI approved vaccine without published clinical trial results August 20, 2022
  • Pitch your Start-up to National/International Venture Capitalists – first ever opportunity provided to Bio-Start-ups by FABA August 19, 2022
  • India’s Clinical Trial Registry might disappear soon and so the history of pharma record August 19, 2022
  • Nearly Half of Pregnant Women in Pfizer Trial Miscarried August 10, 2022
  • Researchers develop Cellulose shoes made by bacteria August 9, 2022
  • Biocon Sdn. Bhd. Enters Malaysia Book of Records as the First & the Largest Integrated Insulin Manufacturing Facility August 5, 2022
  • CBI Arrests of CDSCO officials, a Biocon official & Intermediaries in an alleged bribery case exposed Corruption in Govt and Pharma sector July 27, 2022
  • We are making best hygiene solutions through Biotech applications: Dr Rachna Dave, founder MicroGO July 26, 2022
  • EVENT HIGHLIGHTS: Genome editing as a novel technology for sustainable development July 24, 2022
  • US Military Doctor Testifies under Oath That She Was ORDERED To ‘Cover up’ COVID Vaccine Injuries July 24, 2022
  • Climatic Effect on Marine Biodiversity and their impact on coral reefs July 23, 2022
  • Highlights of India’s first Biotech startup Expo June 13, 2022
  • NTU Singapore scientists develop a ‘fabric’ that turns body movement into electricity June 6, 2022
  • Researchers who jumped into the field from distant disciplines published lower impact work, study finds May 30, 2022
  • Amrita Vishwa Vidyapeetham gets CDSCO nod for clinical trials of first-of-its-kind synthetic jaw-bone graft May 26, 2022
  • AstraZeneca Covid-19 vaccines which uses a chimpanzee adenovirus inked to monkeypox outbreak May 25, 2022
  • Concerns Mount Over COVID-19 ‘Rebounds’ After Treatment With Pfizer’s Paxlovid May 25, 2022
Archives
Categories
  • Articles
  • Articles- Editorials
  • Articles- Guestorials
  • BioControversial
  • BioEvents
  • BioGadgets
  • BioPolicies
  • BioResearch – Academic
  • Biotech News
  • Biotech News – Featured
  • Contents
  • Interviews
  • Interviews – Academia
  • Interviews – Industry
  • SARS- CoV2 & COVID-19 Updates
  • startups
About Us

Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports,  Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology and allied sciences like Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurology, Genetics, Medical Sciences, BioPharma etc.

Call us: _91-9311986177

Email – biotechexpressindia@gmail.com

About Us

About Biotech Express

Advisory and Editorial Board

Contact Us

Policy and Guidelines

Submission policies

Peer review policy    

Copyright policy

 

Follow Us
  • Facebook
  • Twitter
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies. Copyright © 2013-2020 Biotech Express except certain content provided by third parties.

Type above and press Enter to search. Press Esc to cancel.